Change History Table: Original – Amendments (2)

Amendment 2(Dec 22, 2023): BARDA BAA-23-100-SOL-00004 List of Changes:

Amendment 2 (Dec 22, 2023)
1. Suspend AOI 9.4 COVID-19 Monoclonal Antibody Therapeutics for Treatment

Amendment 1(Nov 9, 2023): BARDA BAA-23-100-SOL-00004 List of Changes:

Amendment 1 (Nov 9, 2023)
1. Updates to Overview Information – • Updated Research and Development Opportunity Description • Updated General Market Research (TechWatch Program), • Updated Application Process, • Updated Contract and Submission Information, • Updated Electronic Portal Submission Instructions 2. Updates to Background 3. Updates to Part I: Development and Technical Objectives 4. Updates to Part IV: Pre-Submission Call and Quad Chart/Market Research Abstract Instructions (Stages 1 & 2) • Updated Figure 1. BARDA BAA Process Flow Chart • Updated Stage 1: Pre-submission Call with Technical POC 5. Updates to Part VI: Proposal Instructions (Stage 3) • Updates to Stage 3: Proposal Precreation o Section M. Past Performance Information & o Vol. II, Attachment 10: Past Performance o Vol. II, Attachment 11: Reason for the Proposed Award Type 6. Updates to Part VII: Proposal Evaluation 7. Updates to Area of Interest #6: Burn and Blast Medical Countermeasures • Updated TRL Requirement 8. Updates to Area of Interest #7: Diagnostics • Updated AOI 7.1.3 Biothreat Agent Diagnostics: Filovirus Point-of-Care and Remote Settings • Updated AOI 7.3.1 Influenza Home-Use Testing (for OTC or Prescription At-home)

Amendment 1 (Nov 9, 2023)
• Updated AOI 7.3.3 Point-of-Care Multiplex Assay for Detection of Influenza Virus 9. Updates to Area of Interest #9: IEID Therapeutics • Added new Area of Interest 9.4 COVID-19 Monoclonal Antibody Therapeutics for Treatment • Updated Additional Assessment Factors for the Specific Topic AOIs 10. Suspend AOI #11: COVID-19 Immune Assay(s) Development and Implementation